Sanofi Receives FDA Approval for Soliqua

Sanofi (NYSE:SNY) has announced that the FDA has approved Soliqua for treating adults with type 2 diabetes.
According to the press release:

“Soliqua 100/33 will be delivered in a single pre-filled pen for once-daily dosing covering 15 to 60 Units of insulin glargine 100 Units/mL and 5 to 20 mcg of lixisenatide using SoloStar technology, the most frequently used disposable insulin injection pen platform in the world.² Soliqua 100/33 will be available in U.S. retail pharmacies in January 2017.”

Elias Zerhouni, president of global R&D at Sanofi, said the following:

“Soliqua 100/33 is an alternate new approach that can help adults living with type 2 diabetes uncontrolled on basal insulin or lixisenatide to reach their treatment goal.”

Read the full press release here.